Gilead, Arcellx close agreement on developing T-cell therapy for multiple myeloma
luismmolina/iStock via Getty Images         

Gilead Sciences' (NASDAQ:GILD) Kite unit and Arcellx (NASDAQ:ACLX) have finalized a collaboration for the further development of CART-ddBCMA, the latter company's lead treatment for relapsed or refractory multiple myeloma.
The T-cell therapy, currently in phase 2, will be jointly commercialized in the US and by Kite in other countries.
Arcellx (ACLX) received a $225M upfront payment and $100M equity investment from Kite as part of the deal.